Nimorazole companion diagnostic - Azanta

Drug Profile

Nimorazole companion diagnostic - Azanta

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Aarhus
  • Developer Azanta; European Organisation for Research and Treatment of Cancer; The Christie NHS Foundation Trust; University of Aarhus
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 23 Aug 2017 Nimorazole companion diagnostic is still in phase III trials for Head and Neck cancer (Diagnosis) in Denmark, France, Belgium, United Kingdom, Switzerland, Netherlands, Germany, Australia (NCT01880359) (NCT02661152) (NCT01950689)
  • 29 Sep 2014 Azanta acquires rights to companion diagnostic of nimorazole from the University of Aarhus
  • 01 May 2014 Phase-III clinical trials in Head and neck cancer (Combination therapy, Diagnosis, First-line therapy, Late-stage disease) in Switzerland, Netherlands, Germany, Australia (unspecified route) after May 2014 (NCT01880359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top